LINC02066: A Long Intergenic Non-Protein Coding RNA and Potential Drug Target

Target Name: LINC02066

NCBI ID: G105374158

LINC02066

Other Name(s): Long intergenic non-protein coding RNA 2066, transcript variant X2 | long intergenic non-protein coding RNA 2066 | LINC02066 variant X2

LINC02066: A Long Intergenic Non-Protein Coding RNA and Potential Drug Target

LINC02066 is a long non-protein-coding RNA (lncRNA) molecule that has been identified in various genomes, including human, mouse, and rat. It is characterized by a unique structure that consists of a series of non-coding exons separated by introns, which are then translated into proteins. LINC02066 has been assigned a gene symbol of LINC02066 and is also known as X2 RNA.

Molecular Structure and Function

The molecular structure of LINC02066 is characterized by the presence of a stem-loop structure that is composed of four conserved nucleotides. The stem-loop region is responsible for the formation of a stem-loop hairpin, which is a common structural motif that is involved in the regulation of gene expression.

The LINC02066 protein is a 24.5 kilobase (kb) long RNA molecule that contains 19 exons. It is expressed in various tissues and organs, including brain, heart, liver, and muscle. LINC02066 has been shown to play a role in the regulation of gene expression and has been associated with various cellular processes, including cell growth, differentiation, and metabolism.

Potential Drug Target

The unique structure of LINC02066 and its involvement in cellular processes make it an attractive drug target. Several studies have suggested that LINC02066 may be a potential drug target for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders.

One of the reasons for the potential of LINC02066 as a drug target is its unique structure, which allows for the targeting of specific regions of the molecule. Additionally, LINC02066 has been shown to play a role in the regulation of gene expression, which may provide insight into its potential mechanisms of action.

Another potential drug target for LINC02066 is its involvement in various cellular processes that are affected by various diseases. For example, LINC02066 has been shown to be involved in the regulation of cell adhesion, which is a process that is affected in various diseases, including cancer. Additionally, LINC02066 has been associated with the regulation of cellular metabolism, which is a process that is affected in diseases such as diabetes.

Conclusion

LINC02066 is a long non-protein-coding RNA molecule that has been identified in various genomes. Its unique structure and involvement in various cellular processes make it an attractive drug target. The potential of LINC02066 as a drug target for various diseases makes it a promising molecule for further research and development.

Targeting LINC02066 may provide new insights into the regulation of gene expression and the underlying mechanisms of various diseases. Further studies are needed to determine the full potential of LINC02066 as a drug target and to develop effective strategies for its development as a new treatment option.

Protein Name: Long Intergenic Non-protein Coding RNA 2066

The "LINC02066 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02066 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets